Skip to content
Screener

Enovis ENOV Noncontrolling interests in subsidiaries

Noncontrolling interests in subsidiaries at other companies

Zimmer Biomet Holdings logo
Zimmer Biomet HoldingsZBH
$8.7M-6.5%
ESAB logo
ESABESAB
$45.54M+8.1%
Bioventus logo
BioventusBVS
$49.11M+22.6%
Encompass Health Corporation logo
Encompass Health CorporationEHC
$786.7M+8.9%
VAT
InnovateVATE
$13.3M-33.2%

Other financials

Income statement

See full
Revenue$582.8M+3.2%
Gross profit$359.2M+7.3%
Operating income$17.4M+204%
Net income-$1.2M+96.8%
EPS (diluted)-$0.02+96.9%

Balance sheet

See full
Cash & equivalents$12.6M-71.5%
Total debt$1.3B-6.4%
Total equity$1.5B-42.7%
Total assets$3.8B-25.0%

Cash flow

See full
Operating cash flow$75.0M+57.1%
CapEx$43.9M-1.1%
Free cash flow$31.1M

Valuation

See full
Market cap$1.53B-5.5%
Enterprise value$2.83B-4.9%
P/S0.7×-0.1×

Profitability

See full
Gross margin61.1%+3.5pp
Operating margin-45.1%+19.4pp
Net margin-48%+17.7pp
FCF margin-3.1%-1.1pp

Returns & leverage

See full
Return on equity-54.3%+672pp
Debt / equity0.9×+0.3×
Current ratio-0.3×

Where this comes from

Reported directly by Enovis in its filing.

Tagged under the XBRL concept us-gaap:MinorityInterest.

The source filing: Enovis’s 10-Q, filed August 6, 2026.

Filed
Aug 6, 2026, 6:45 AM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001420800-26-000035
Line itemJuly 3, 2026December 31, 2025
Common stock, $0.001 par value; 133,333,333 shares authorized; 57,665,074 and 57,194,781 shares issued and outstanding as of July 3, 2026 and December 31, 2025, respectively5857
Additional paid-in capital3,065,6673,048,414
Accumulated deficit(1,477,417)(1,467,463)
Accumulated other comprehensive loss(111,241)(91,363)
Total Enovis Corporation equity1,477,0671,489,645
Noncontrolling interest2,0982,257
Total equity1,479,1651,491,902
Total liabilities and equity$3,766,126$3,834,737

Item 1. Financial Statements

FAQ

What is Enovis's noncontrolling interests in subsidiaries?
Enovis (ENOV) reported noncontrolling interests in subsidiaries of $2.1M in Q2 2026.
How has Enovis's noncontrolling interests in subsidiaries changed year-over-year?
Enovis's noncontrolling interests in subsidiaries decreased by 24.3% year-over-year, from $2.77M to $2.1M.
What is the long-term trend for Enovis's noncontrolling interests in subsidiaries?
Over 5 years (2020 to 2025), Enovis's noncontrolling interests in subsidiaries has grown at a -44.9% compound annual growth rate (CAGR), from $44.49M to $2.26M.
What does noncontrolling interests in subsidiaries mean?
This represents the portion of a subsidiary's net assets that is owned by outside shareholders rather than the parent company. It is reported within equity to show the total value of the subsidiary's assets and liabilities that are not attributable to the parent. It reflects the non-controlling stake in consolidated entities.

Ask your AI about Enovis's noncontrolling interests in subsidiaries.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude